Related references
Note: Only part of the references are listed.PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
Muhammad A. Khattak et al.
ONCOLOGIST (2020)
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
Francesco Facchinetti et al.
EUROPEAN JOURNAL OF CANCER (2020)
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data
Filippo G. Dall'Olio et al.
LUNG CANCER (2020)
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience
Filippo G. Dall'Olio et al.
LUNG CANCER (2020)
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
Ernest Nadal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer
Yasuhiro Koh et al.
CLINICAL LUNG CANCER (2019)
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Massimo Cristofanilli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine
Bing Tong et al.
FUTURE ONCOLOGY (2019)
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
Menno Tamminga et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Melanie Janning et al.
CANCERS (2019)
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
C. R. Lindsay et al.
EUROPEAN JOURNAL OF CANCER (2019)
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
Nicolas Guibert et al.
LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
Chunyan Yue et al.
ONCOIMMUNOLOGY (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
Vincenzo Di Nunno et al.
FRONTIERS IN ONCOLOGY (2018)
The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer
Arutha Kulasinghe et al.
CANCER MEDICINE (2018)
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
M. Ilie et al.
ANNALS OF ONCOLOGY (2018)
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
Enrico Munari et al.
ONCOTARGET (2017)
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C. Tumeh et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer
Zixuan Zhang et al.
RESPIROLOGY (2016)
Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation
Marta Tellez Gabriel et al.
CLINICAL CHEMISTRY (2016)
Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC
Phil A. J. Crosbie et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection
Clara Bayarri-Lara et al.
PLOS ONE (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The detection of EpCAM+ and EpCAM- circulating tumor cells
Sanne de Wit et al.
SCIENTIFIC REPORTS (2015)
Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research
P. K. Grover et al.
ANNALS OF ONCOLOGY (2014)
Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches
Matthew G. Krebs et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
J. Tol et al.
ANNALS OF ONCOLOGY (2010)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Share Paper
